Effects of OPRM1 and CYP3A41G gene polymorphisms on opioid pharmacodynamics in sepsis patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000034581

Enrollment

Unknown

Registered

2020-07-10

Start date

2020-08-01

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

case series:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis criteria of sepsis 3.0; 2. 18-year-old adult patients; 3. The RASS score of sedation target was - 2 to + 1. Deep sedation was used in severe ARDS; 4. Fentanyl or sufentanil or remifentanil was used for analgesia;

Exclusion criteria

Exclusion criteria: 1. Patients who used fentanyl or sufentanil or remifentanil for analgesia; 2. The prognosis of basic diseases is bad and may become the main cause of death; 3. The treatment cost is tight, and it is estimated that the treatment can not be completed by the observer.

Design outcomes

Primary

Measure	Time frame
OPRM1 genetype;CYP3A41G genetype;dosage of fentanyl;length of hospital time;Mechanical ventilation time;SOFA score;mortality;T cell function;	—

Countries

China

Contacts

Public ContactGuo Hong

The First Hospital of Lanzhou University

guohong980324@163.com+86 13893475589

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026